

Clinical trials of SR123781A

TrialResults-center www.trialresultscenter.org

1 thrombosis prevention

Trial	Treatments	Patients	Trials design and methods
SR123781A vs enoxaparin			
DRIVE , 2008 [NCT00338897] n=854/169 follow-up: 5-10 days	SR123781A for 5-10 days, doses ranging from 0.25 to 4.0 mg daily for 10 days versus enoxaparin 40 mg	patients undergoing total hip replacement surgery	Parallel groups double blind 12 countries

More details and results :

- antithrombotics for thrombosis prevention in orthopedic surgery at <http://www.trialresultscenter.org/go-Q37>
- antithrombotics for thrombosis prevention in elective hip replacement at <http://www.trialresultscenter.org/go-Q39>
- pentasaccharide for thrombosis prevention in orthopedic surgery at <http://www.trialresultscenter.org/go-Q188>
- pentasaccharide for thrombosis prevention in all type of patients at <http://www.trialresultscenter.org/go-Q396>

References

DRIVE, 2008:

Lassen MR, Dahl O, Mismetti P, Zielske D, Turpie AG SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) study. J Am Coll Cardiol 2008 Apr 15;51:1498-504 [[18402906](#)]